ArticleEClinicalMedicine2024

Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial.

Yan Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.